- Home
- NMRK vs SUPN Comparison
NMRK vs SUPN Comparison
Compare NMRK & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMRK | SUPN |
|---|---|---|
| Founded | 1929 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2017 | 2012 |
Fundamental Metrics
Financial Performance| Metric | NMRK | SUPN |
|---|---|---|
| Price | $17.32 | $47.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $19.40 | ★ $63.25 |
| AVG Volume (30 Days) | ★ 1.2M | 664.8K |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | ★ 0.69% | N/A |
| EPS Growth | ★ 94.50 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $3,160,782,000.00 | $681,539,000.00 |
| Revenue This Year | $21.82 | $8.32 |
| Revenue Next Year | $10.10 | $23.36 |
| P/E Ratio | $29.40 | ★ N/A |
| Revenue Growth | ★ 20.95 | 4.54 |
| 52 Week Low | $9.65 | $29.16 |
| 52 Week High | $19.84 | $57.65 |
Technical Indicators
Market Signals| Indicator | NMRK | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 50.92 | 53.47 |
| Support Level | $16.47 | $45.36 |
| Resistance Level | $17.61 | $47.26 |
| Average True Range (ATR) | 0.59 | 1.23 |
| MACD | 0.07 | 0.36 |
| Stochastic Oscillator | 63.32 | 92.10 |
Price Performance
Historical ComparisonAbout NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.